baricitinib, thyrosin kinase inhibitors, Janus kinases JAK1 and JAK2 inhibitor
DISEASE INTERVENTION COMPARISON RESULTS
N Engl J Med. 2017 02 16;376(7):652-662 Randomized Controlled Trial, Multicenter Study
IN rheumatoid arthritis, active despite methotrexate therapy The Use of
baricitinib, thyrosin kinase inhibitors, Janus kinases JAK1 and JAK2 inhibitor
As Treatment, Chronic
Is better Than
placebo, or adalimumab, an anti-tumor necrosis factor α (TNFalpha) monoclonal antibody
To achieve clinical improvement at 3 moths: 70% patients on baricitinib, 61% adalimumab, 40% placebo. Adverse events, including infections, were more frequent with baricitinib and adalimumab